



(12) **United States Design Patent**
Bayer et al.

(10) **Patent No.:** **US D828,366 S**
(45) **Date of Patent:** **** Sep. 11, 2018**

(54) **DISPLAY SCREEN OR PORTION THEREOF WITH GRAPHICAL USER INTERFACE**

(71) Applicant: **Smiths Medical ASD, Inc.**, Plymouth, MN (US)

(72) Inventors: **Nancy Bayer**, Arden Hills, MN (US); **Jennifer Tsai**, Stillwater, MN (US); **Gail Bynum**, Brooklyn Park, MN (US); **Lisa Hoh**, Saint Paul, MN (US); **Chris Pickles**, Bridport (GB); **Kou Lor**, Saint Paul, MN (US); **Janet Shallbetter**, Brooklyn Park, MN (US)

(73) Assignee: **Smiths Medical ASD, Inc.**, Plymouth, MN (US)

(**) Term: **15 Years**

(21) Appl. No.: **29/587,858**

(22) Filed: **Dec. 15, 2016**

(51) **LOC (11) Cl.** **14-04**

(52) **U.S. Cl.**
USPC **D14/485**

(58) **Field of Classification Search**
USPC D14/485-495
CPC G06F 17/211; G06F 17/212; G06F 3/1251; G06F 3/0481; G06F 2203/04807
See application file for complete search history.

(56) **References Cited**

U.S. PATENT DOCUMENTS

4,756,706 A	7/1988	Kerns et al.	
D599,377 S *	9/2009	Jewitt	D14/489
D719,963 S *	12/2014	Hobbs	D14/486
D750,099 S *	2/2016	Seo	D14/485
D753,174 S *	4/2016	Cojuangco	D14/486
D757,760 S *	5/2016	Ku	D14/485
D759,044 S *	6/2016	Zhang	D14/485
D760,758 S *	7/2016	Iwamoto	D14/486
D765,667 S *	9/2016	Lu	D14/485

D766,949 S *	9/2016	Johnson	D14/486
D767,601 S *	9/2016	Zhou	D14/486
D768,166 S *	10/2016	Kim	D14/486
D770,507 S *	11/2016	Umezawa	D14/486
D775,653 S *	1/2017	Hoffman	D14/486
D783,028 S *	4/2017	Lee	D14/485
D783,050 S *	4/2017	Kisselev	D14/489
D783,665 S *	4/2017	Caporal	D14/487
D784,374 S *	4/2017	Hao	D14/486

(Continued)

Primary Examiner — Darlington Ly

Assistant Examiner — Daniel J Domino

(74) Attorney, Agent, or Firm — Patterson Thuent Pedersen, P.A.

(57) **CLAIM**

We claim the ornamental design for display screen or portion thereof with graphical user interface, as shown and described.

DESCRIPTION

FIG. 1 is a front view of a display screen or portion thereof with graphical user interface according to a first embodiment of the invention.

FIG. 2 is a front view of a display screen or portion thereof with graphical user interface according to a second embodiment.

FIG. 3 is a front view of the display screen or portion thereof with graphical user interface of FIG. 1 depicted on a device; and,

FIG. 4 is a front view of a display screen or portion thereof with graphical user interface according to a third embodiment.

The broken line showing of an electronic device in FIG. 3 illustrates environmental structure; whereas the broken lines showing a display screen and elements of the graphical user interface illustrate portions of the article. All subject matters depicted in broken lines do not form part of the claimed design.

1 Claim, 4 Drawing Sheets

Neuro

Gammagard 100 mg/mL

Dose	Infusion Volume	1	2	3
<input type="text"/> g	<input type="text"/> mL	4	5	6
Weight	Reservoir Volume	7	8	9
<input type="text"/> kg	<input type="text"/> mL	Next ...	←	0
Concentration				.
100 mg/mL				

Confirm

Delivery Options

(56)

References Cited

U.S. PATENT DOCUMENTS

D784,407	S *	4/2017	Hammerquist	D14/489	2009/0153463	A1	6/2009	Arrizza et al.
D791,153	S *	7/2017	Rice	D14/486	2009/0153595	A1	6/2009	Cozmi et al.
D795,276	S *	8/2017	Pakidko	D14/486	2009/0157432	A1	6/2009	Palmroos et al.
D802,618	S *	11/2017	Walker	D14/487	2009/0171289	A1	7/2009	Davis et al.
D806,098	S *	12/2017	Rahn	D14/486	2009/0177180	A1	7/2009	Rubalcaba, Jr. et al.
D812,635	S *	3/2018	Wei	D14/486	2009/0177991	A1	7/2009	Davis et al.
D813,248	S *	3/2018	Burton	D14/485	2009/0177992	A1	7/2009	Rubalcaba, Jr. et al.
D813,883	S *	3/2018	Amin	D14/485	2009/0183105	A1	7/2009	Teel, IV et al.
D814,480	S *	4/2018	Muller	D14/485	2009/0183147	A1	7/2009	Davis et al.
D814,487	S *	4/2018	Capela	D14/485	2010/0010647	A1	1/2010	Schroeder et al.
D814,518	S *	4/2018	Martin	D14/492	2010/0100037	A1	4/2010	Cozmi et al.
D816,112	S *	4/2018	Toth	D14/488	2011/0276881	A1*	11/2011	Keng G11B 27/034 715/723
2003/0060765	A1	3/2003	Campbell et al.		2012/0130308	A1	5/2012	Silkaitis et al.
2006/0229557	A1	10/2006	Fathallah et al.		2014/0047392	A1*	2/2014	Kim G06F 3/04812 715/846
2008/0103375	A1	5/2008	Kiani		2015/0314066	A1	11/2015	Shimizu
2008/0200870	A1	8/2008	Palmroos et al.					
2008/0281168	A1	11/2008	Gibson et al.					
2009/0153058	A1	6/2009	Feng et al.					

* cited by examiner

Neuro		Gammagard 100 mg/mL		100%		
Dose	g	Infusion Volume	mL	1	2	3
Weight	kg	Reservoir Volume	mL	4	5	6
Concentration	100 mg/mL	Next ...		7	8	9
		Confirm		↵	0	.

FIGURE 1

Neuro		100%	
Gammagard 100 mg/mL			
Initial Rate	mg/kg/min	Step Duration	hh:mm:ss
Plateau Rate	mg/kg/min	Infusion Duration	hh:mm:ss
Step Increment	mg/kg/min	Previous	
		Delivery Options	
1	2	3	
4	5	6	
7	8	9	
↵	0	.	

FIGURE 2




FIGURE 3

NICU		100%	
Ampicillin 100 mg/mL			
Dose	200.00 mg/kg	Infusion Duration	1:00:00 hh:mm:ss
Weight	68.00 kg	Rate	136.00 mL/h
Concentration	100.00 mg/mL	Delivery Options	
<input type="button" value="Confirm"/>			
1	2	3	
4	5	6	
7	8	9	
	0	.	

FIGURE 4